La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Sagimet Biosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Sagimet Biosciences..

Sagimet Biosciences (NASDAQ:SGMT) Azioni, Catena delle Opzioni

SAGIMET BIOSCIENCES INC-A

Sagimet Biosciences

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences Inc

Press Releases

Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

Health Care

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

News

Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Earnings

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week

Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination

SGMT

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Crescent Biopharma

Coherus Oncology

Caribou Biosciences

Foghorn Therapeutics

Genfit

Heron Therapeutics

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Invivyd

Seres Therapeutics

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tenaya Therapeutics

Entrada Therapeutics, Inc. - Common Stock

Comments

Sagimet Biosciences

Sagimet Biosciences (SGMT) Opzioni

Sagimet Biosciences (NASDAQ:SGMT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO